Clinical Trials

To view the clinical trials Valley currently has available, please use the search field or select a clinical specialty from the drop-down list below. Be sure to check back frequently, as we are always adding new studies.

For more information about any of our clinical trials, please email clinicaltrialsresearch@valleyhealth.com or call 201-447-8453. (For cancer clinical trials, please call 201-634-5792.)

Learn more about research and clinical trials at Valley.

Clear All

A081105

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Principal Investigator(s):

  • Jason W. Suh, MD

A151216

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Principal Investigator(s):

  • Jason W. Suh, MD

AEB1102

A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

Principal Investigator(s):

  • Jin Lee, MD

CALGB 30610

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide

Principal Investigator(s):

  • Chad M. DeYoung, MD

Checkmate 816

Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC

Principal Investigator(s):

  • Eli Kirshner, MD

E4512 ALCHEMIST

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Principal Investigator(s):

  • Jason W. Suh, MD

EA5142 ANVIL

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Principal Investigator(s):

  • Jason W. Suh, MD

EA5161

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Principal Investigator(s):

  • Eli Kirshner, MD

EMERGE

Phase 2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX -2011 and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer

Principal Investigator(s):

  • Eli Kirshner, MD

I-ELCAP

International Early Lung Cancer Action Program

Principal Investigator(s):

  • Robert J. Korst, MD